Treatment of murine lupus with cDNA encoding IFN-γR/Fc

被引:136
作者
Lawson, BR
Prud'homme, GJ
Chang, YG
Gardner, HA
Kuan, J
Kono, DH
Theofilopoulos, AN
机构
[1] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA
[2] McGill Univ, Dept Pathol, Montreal, PQ, Canada
关键词
D O I
10.1172/JCI10167
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
IFN-gamma, a pleiotropic cytokine, is a key effector molecule in the pathogenesis of several autoimmune diseases, including lupus. Importantly, deletion of IFN-gamma or IFN-gamma R in several lupus-predisposed mouse strains resulted in significant disease reduction, suggesting the potential for therapeutic intervention. We evaluated whether intramuscular injections of plasmids with cDNA encoding IFN-gamma R/Fc can retard lupus development and progression in MRL-Fas(lpr) mice. Therapy significantly reduced serum levels of IFN-gamma, as well as disease manifestations (autoantibodies, lymphoid hyperplasia, glomerulonephritis, mortality), when treatment was initiated at the predisease stage, particularly when IFN-gamma R/Fc expression was enhanced by electroporation at the injection site. Remarkably, disease was arrested and even ameliorated when this treatment was initiated at an advanced stage. This therapy represents a rare example of disease reversal and makes application of this nonviral gene therapy in humans with lupus (and perhaps other autoimmune/inflammatory conditions) highly promising.
引用
收藏
页码:207 / 215
页数:9
相关论文
共 50 条
  • [1] Gene transfer into muscle by electroporation in vivo
    Aihara, H
    Miyazaki, J
    [J]. NATURE BIOTECHNOLOGY, 1998, 16 (09) : 867 - 870
  • [2] Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune Myasthenia gravis in mice
    Balasa, B
    Deng, CS
    Lee, J
    Bradley, LM
    Dalton, DK
    Christadoss, P
    Sarvetnick, N
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (03) : 385 - 391
  • [3] Interferon-γ is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice
    Balomenos, D
    Rumold, R
    Theofilopoulos, AN
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (02) : 364 - 371
  • [4] Cellular responses to interferon-gamma
    Boehm, U
    Klamp, T
    Groot, M
    Howard, JC
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 : 749 - 795
  • [5] SYSTEMIC LUPUS-ERYTHEMATOSUS - EMERGING CONCEPTS .2. DERMATOLOGICAL AND JOINT DISEASE, THE ANTIPHOSPHOLIPID ANTIBODY SYNDROME, PREGNANCY AND HORMONAL-THERAPY, MORBIDITY AND MORTALITY, AND PATHOGENESIS
    BOUMPAS, DT
    FESSLER, BJ
    AUSTIN, HA
    BALOW, JE
    KLIPPEL, JH
    LOCKSHIN, MD
    [J]. ANNALS OF INTERNAL MEDICINE, 1995, 123 (01) : 42 - 53
  • [6] Bullard DC, 1997, J IMMUNOL, V159, P2058
  • [7] Daikh DI, 1997, J IMMUNOL, V159, P3104
  • [8] Gene therapy in autoimmune diseases
    Evans, CH
    Whalen, JD
    Ghivizzani, SC
    Robbins, PD
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1998, 57 (03) : 125 - 127
  • [9] TREATMENT OF MURINE LUPUS WITH CTLA4IG
    FINCK, BK
    LINSLEY, PS
    WOFSY, D
    [J]. SCIENCE, 1994, 265 (5176) : 1225 - 1227
  • [10] Haas C, 1998, J IMMUNOL, V160, P3713